# Study of Gemcabene in Adults With FPLD

> **NCT03508687** · PHASE1,PHASE2 · COMPLETED · sponsor: **Elif Oral** · enrollment: 5 (actual)

## Conditions studied

- Familial Partial Lipodystrophy
- Hypertriglyceridemia
- Fatty Liver
- NASH - Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** 300mg Gemcabene
- **DRUG:** 600mg Gemcabene

## Key facts

- **NCT ID:** NCT03508687
- **Lead sponsor:** Elif Oral
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-13
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2020-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03508687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03508687, "Study of Gemcabene in Adults With FPLD". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03508687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*